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Background: Vitamin D deficiency is widespread in New Zealand, confers multiple health risks, and may be
particularly common among people with psychiatric illness. We studied vitamin D status in an unselected sample of
adult psychiatric inpatients in Hamilton (latitude 37.5 S) during late winter.
Methods: We recruited 102 consenting subjects and measured 25-hydroxy vitamin D3 levels in venous blood using
a competitive electrochemiluminescence immunoassay. In addition to descriptive statistics, we used one-sample t-
tests to determine the extent to which ethnic and diagnostic subgroups fell below the vitamin D deficiency
threshold of 50 nM.
Results: 75 subjects (74%) had vitamin D levels <50 nM and thus had at least mild deficiency, while 19 (19%) were
severely deficient with levels <25 nM. Rates of deficiency were comparable for men and women; only the former
showed a correlation of vitamin D levels with age (r = 0.45, p< 0.01). Maori participants constituted half the sample
(n = 51) and were more likely to be deficient than their European counterparts (p = 0.04). Vitamin D also varied by
diagnosis, with schizophrenia associated with markedly lower levels than mania and depression (p< 0.001).
Conclusions: Vitamin D deficiency is prevalent in the psychiatric inpatient setting in New Zealand and may be
relevant to poor physical health outcomes, notably among Maori and those with schizophrenia. These findings
support proposals to provide vitamin D supplementation, particularly during the winter months.Background
Vitamin D plays a central role in the regulation of cal-
cium status and is essential for bone health [1]. In the
last decade, evidence has accumulated that vitamin D
also has other important physiological roles, and is rele-
vant to a variety of clinical conditions, including mental
illness. For example, a Finnish cohort of boys receiving
supplements during the first year of life showed a
decreased risk of developing schizophrenia by age 31 [2].
Vitamin D also appears to influence mood symptoms,
based on epidemiological [3] and clinical trial evidence
[4].
There is some controversy regarding normal and opti-
mal ranges for vitamin D. Because bone disease is clearly
associated with blood levels <25 nM, this threshold is
generally accepted as indicating definite deficiency.
Levels between 25 and 50 nM are in a grey zone, com-
monly considered ‘insufficiency’, although some experts* Correspondence: david.menkes@waikatodhb.health.nz
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reproduction in any medium, provided the orinsist this still constitutes deficiency [5]. Optimum levels
are now considered to be around 75 nM and possibly
higher [1,6].
New Zealand’s population appears to have widespread
vitamin D deficiency [7-9]; based on its latitude (35-46
degrees S) it is considered to be in a ‘vulnerable’ region
[10] with marked seasonal fluctuations in ultraviolet
light exposure. In addition, more than 30% of the popu-
lation has darker skin pigmentation (14.6% Maori; 9.2%
Asian; 6.9% Pacific) [11] and among these populations
vitamin D deficiency is likely to be even more common,
as has been demonstrated in Maori compared to Euro-
pean children [8]. Sunscreen use is prevalent, reducing
vitamin D synthesis, and there is little fortification of
food [9] compared with North America and Western
Europe. These regions also have prevalent deficiency
despite repeated calls by authorities to increase the
recommended intake of vitamin D [12].
Limited evidence indicates that vitamin D deficiency is
common in psychiatric inpatient samples in Germany
[13], the UK [14] and Australia [15]; corresponding dataLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association of vitamin D levels with gender,
ethnicity and diagnosis
Group n vitamin D (nM) one-sample test
mean s.d. t p
Entire sample 102 42.7 21.5 3.45 .001
Male 56 42.6 20.2 2.73 .008
Female 46 42.7 23.2 2.14 .04
Maori 51 37.8 20.3 4.29 <.001
Non-Maori 51 47.5 21.7 0.82 .42
Schizophrenia 38 34.5 15.4 6.23 <.001
Schizoaffective 11 42.8 9.00 2.65 .024
Bipolar Disorder 19 49.4 29.2 0.09 .93
Depression 17 47.5 25.7 0.40 .70
Miscellaneous 17 48.4 20.6 0.32 .75
One sample t-tests were used to estimate the extent to which vitamin D levels
in the study population and sub-groups differed from the deficiency threshold
of 50 nM.
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direct evidence indicates that deficiency is likely to be, if
anything, worse than in the general population. Mental
disorder is associated with poor diet and limited outdoor
exercise, thus tending to limit vitamin D intake and syn-
thesis. Moreover, those with darker skin, particularly
Maori, tend both to have higher rates of deficiency and
also to be over-represented in psychiatric inpatient
populations [16]. Based on the foregoing, we aimed to
measure vitamin D levels in psychiatric patients in Ham-
ilton, New Zealand (latitude 37.5oS) during the late win-
ter when levels are near their nadir [7,17]. Our
secondary aims were to investigate the possible role of




The eligible population included 132 adult patients (18–
65 years) admitted to the region’s inpatient psychiatric
facility between 29 July and 31 August 2010. 102 (78% of
those eligible) gave informed consent and had serum
samples collected by venepuncture. Ethnicity was deter-
mined according to the New Zealand Census procedure
2001, with particular attention paid to evidence of Maori
identity by descent. Clinical diagnosis was established at
hospital discharge based on DSM-IV criteria. The study
was approved by the Northern Y Regional Ethics Com-
mittee (NTY/10/EXP/061).
Biochemistry
Plasma 25-hydroxy vitamin D3 was determined using a
competitive electrochemiluminescence immunoassay
(E170, Roche diagnostics, Mannheim, Germany). Cross
reactivity with 25-hydroxy vitamin D2 and with 24,25-
dihydroxy vitamin D is less than 10% and 20% respect-
ively. The coefficient of variation is <8% at each concen-
tration of internal control (35, 50 and 75 nM). Samples
were analysed by the Waikato Hospital laboratory, certi-
fied by the relevant international accreditation agency
(www.ianz.govt.nz/). By consensus in New Zealand
(www.bpac.org.nz/magazine/2011/june/vitamin-d.asp),
and in accord with studies mentioned in the Introduc-
tion, this laboratory defines levels between 25–50 nM
(10–20 ng/ml) and those below 25 nM (10 ng/ml) as in-
dicating mild and severe deficiency, respectively.
Data analysis
Data were collected using an Excel spreadsheet and ana-
lysed using SPSS version 19. One-sample tests were used to
determine the extent to which ethnic and diagnostic sub-
groups fell below the vitamin D deficiency threshold of 50
nM. Parametric correlations and partial correlations were
calculated to estimate the effect of age, and Fisher’s ExactTest to identify differences in deficiency rates by category
(gender, ethnicity, diagnosis). Cross-tabulation and
Cramer’s V test were used to determine the association of
psychiatric diagnoses with ethnicity.
Results
The final sample included 102 subjects, of whom 56
were men and 51 were of Maori ethnicity. Vitamin D
levels varied from 10 – 170 nM; mean values by gender,
ethnicity, and diagnosis are presented in Table 1. Sub-
optimal levels (<75 nM) were detected in 91% of
subjects, and at least mild deficiency (<50 nM) in 74%,
with comparable proportions of men (70%) and women
(76%). Severe deficiency (<25 nM) was seen in 19%
overall (16% of men and 22% of women, p = 0.61, Fisher’s
Exact Test). There was thus no gender effect regarding
overall rates of vitamin D deficiency, but there was a Sex
x Age interaction, with men showing significant positive
relationship (r = 0.45, p< 0.01) not seen among women
(r = 0.11, p< 0.5). Maori men, however, were younger
than their non-Maori counterparts by 4 years on aver-
age. A partial correlation was calculated to examine the
possible role of ethnicity in the observed age effect for
men. The resulting comparable correlation (rparti = 0.424,
p = 0.002) indicates that the age effect is independent of
ethnicity.
An ethnic difference in rates of vitamin D deficiency was
identified based on 51 patients with verified Maori identity;
14 of these were severely deficient (<25 nM) compared to
5/51 of non-Maori (p=0.04, Fisher’s Exact Test, see Table 2).
As shown in Table 1, mean levels in the Maori group were
significantly lower than the non-Maori (mean difference=
9.7 nM, 95% CI=1.4 to 18.0, t = 2.33, p=0.022). One-
sample statistics showed that Maori were, on average,
significantly below the 50 nM deficiency threshold
Table 2 Vitamin D deficiency rates by diagnostic group,
ethnicity, and gender




all >50 25–50 <25 50 25
Entire sample 102 27 56 19 73.5 18.6
Schizophrenia
spectrum
49 7 29 13 85.7 26.5
Maori 34 3 20 11 91.2 32.3
male 20 3 11 6 85.0 30.0
female 14 0 9 5 100 35.7
non-Maori 15 4 9 2 73.3 13.3
male 10 4 4 2 60.0 20.0
female 5 0 5 0 100 0.0
Other diagnoses 53 20 27 6 62.3 11.3
Maori 17 4 10 3 76.5 17.6
male 10 3 5 2 70.0 20.0
female 7 1 5 1 85.7 14.3
non-Maori 36 16 17 3 55.6 8.3
male 16 6 9 1 62.5 6.3
female 20 10 8 2 50.0 10.0
Cases were assigned to categories according to vitamin D level; percentages
with mild (<50 nM) and severe (<25 nM) deficiency are summarized in the
right hand columns.
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the same was not true of non-Maori.
Vitamin D levels were also found to vary by diagnosis,
as shown in Table 1. Among the 19 participants with
severe deficiency (<25 nM), 13 had a diagnosis of
schizophrenia. This equates to 34% of participants with
that diagnosis, compared to 9.4% of other participants
(n = 102, p = 0.003, Fisher’s Exact Test). Taken together,
disorders in the schizophrenia spectrum (schizophrenia
and schizoaffective disorder) were over-represented
among those with Vitamin D deficiency (Table 2) and
had markedly reduced average levels (n = 49, mean = 36.4
nM, one-sample t = 6.58, p< 0.001) compared to the
other diagnostic groups, none of which showed a mean
difference from the deficiency threshold of 50 nM
(Table 1).
As is apparent in Table 2, Maori appear over-
represented in disorders in the schizophrenia spectrum,
raising the question of to what extent the effects of ethni-
city and diagnosis, described above, may be confounded.
We first conducted a cross-tabulation of diagnosis by eth-
nicity, confirming a highly significant association of Maori
ethnicity with schizophrenia and schizoaffective disorder
in our inpatient sample (Cramer’s V=0.415, p< 0.001,
n = 102). Comparing ethnicities within the schizophrenia
spectrum showed Maori to have a lower mean vitamin D
level (34.0+ 14.3 nM, n= 34) than Europeans (41.6 + 14.1
nM, n= 15) but this difference failed to reach statisticalsignificance (t = 1.71, p = 0.093, df = 47). Based on this
small sample, it thus appears that Maori ethnicity and
schizophrenia are associated with each other, and both
contribute to low vitamin D.
Given the finding of excess vitamin D deficiency in
schizophrenia, we hypothesized that this might arise
from patients with this diagnosis spending relatively less
time outdoors. Lacking a specific index of an individual’s
sun exposure, we examined time in hospital as a proxy
measure. For each participant, we determined days in
hospital during the 180 days preceding vitamin D sam-
pling and found a weak relationship in the expected dir-
ection between hospitalisation and vitamin D (r =−0.18,
n = 102, p = 0.072). Also as expected, patients with
schizophrenia and schizoaffective disorder had been on
average hospitalised longer (mean = 24.7 + 41.9 days)
than other diagnoses (mean = 13.2 + 29.5 days, t = 1.59,
p = 0.12) but this difference was not significant and can-
not account for the striking association of diagnosis with
vitamin D.
Discussion
Our results indicate a substantial frequency of vitamin D
deficiency in a New Zealand inpatient psychiatric popu-
lation, and accord with evidence of widespread defi-
ciency in the country generally [7-9], and in psychiatric
samples overseas [13-15]. In the southern province of
Canterbury, the population is generally exposed to less
ultraviolet light than Waikato – being an average of 7
degrees further from the equator. A careful epidemio-
logical study in Canterbury found an 89% rate of at least
mild deficiency (<50 nM) and 35% severe deficiency
(<25 nM) during winter (7). These rates are higher than
in our clinical sample, although there is no available
Waikato norm for comparison. It is thus possible that
our results reflect the general Waikato population.
Previous studies performed in nearby Auckland (lati-
tude 36.5oS compared to Hamilton 37.5oS) [17,18] found
vitamin D deficiency to be more frequent in women
than men; in our sample there was only a slight, insig-
nificant excess of women with severe deficiency. Our
sample of younger and middle-aged adults (18–65) did
however show a correlation of vitamin D levels with age
in men but not women, as was found in a Swedish study
[19]. This may explain why the Auckland studies, which
focused on older adults, found significantly higher levels
in men.
We found lower mean vitamin D levels among Maori
(Table 1), who were also more than twice as likely as
Europeans to have severely deficient levels below 25 nM
(Table 2). The generally darker Polynesian skin colour
may explain this effect, as was suggested for the compar-
able difference found in New Zealand children [8]. Low
vitamin D is associated with an increased risk of
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[20,21]; this may be of particular relevance to Maori
whose already elevated cardiometabolic risk appears exa-
cerbated by antipsychotic treatment [22].
Individuals with vitamin D levels below 25 nM may
benefit from supplementation, particularly with regard
to cardiovascular and bone health [20,21,23], but it is
unclear to what extent deficiency and its remediation
may affect our patients’ mental disorder. In the case of
mood disorder there is suggestive evidence that it may
be helpful based on the reported epidemiological associ-
ation between low vitamin D levels and depressive
symptoms [24] and positive results from a trial of sup-
plementation [4].
The observed excess of vitamin D deficiency among
patients with schizophrenia and schizoaffective disorder is
intriguing. While their slightly greater time in hospital can-
not account for this difference, it may be that these patients
are generally less likely to spend time outdoors and thus
synthesize less of the vitamin. Another possibility, suggested
by in vitro studies but yet to verified in patients, is that anti-
psychotic drug treatment may inhibit vitamin D synthesis
[25]. Previous clinical studies have produced mixed results;
one found excess vitamin D deficiency in schizophrenia
and autism compared to other outpatient diagnoses [19],
another reported comparably reduced vitamin D in in-
patient schizophrenia and depression [13] and a third
showed no difference between patients with psychosis and
matched controls [26]. It remains a possibility that vitamin
D abnormalities in early life are associated with the patho-
genesis of schizophrenia [2,27].
Many countries have high rates of vitamin D defi-
ciency, despite mandatory fortification of foods in, for
example, North America, Western Europe, and Austra-
lia. Such a policy is yet to be implemented in New Zea-
land. Supplementation is inexpensive, around $1 per
month, and is reported to have few side effects and little
toxicity [28] even when large doses are used [29]. At the
behest of a government agency (the Accident Compen-
sation Corporation), elderly rest home populations in
New Zealand are now routinely supplemented with vita-
min D in order to reduce the risk of falls causing frac-
tures and other injuries [23]. There are, as yet, no
guidelines on supplementation of psychiatric patients in
New Zealand.
Conclusions
The observed prevalence of vitamin D deficiency in our
psychiatric inpatient population supports the idea that
supplementation should be more generally available, and
perhaps routinely prescribed, given its low cost, lack of
adverse effects and multiple potential benefits. It is our
experience that ‘natural therapies’ are popular with psy-
chiatric patients; this may facilitate uptake of suchtreatment, at least during inpatient admission. Supple-
mentation may be of particular benefit to Maori and to
patients with schizophrenia; both groups have character-
istically poor physical health outcomes and were found
in this study to have exceptionally low vitamin D levels.
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